CUDC-101

Aliases: CUDC101, 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide
Catalog No: 14060 Format: 25 mg $500 Buy
Catalog No: 14061 Format: 5 mg $125 Buy
Application: Histone Acetylation (HAT & HDAC)

Chemical Properties

MW = 434.5
C24H26N4O4
CAS 1012054-59-9
MP = 188-190°C
>99% (HPLC); NMR (Conforms)

Description

A novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2 (IC50 = 4.4 nM, 2.4 nM and 15.7 nM respectively) (ref 1). It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors (ref 1,2).

Contents

White to off-white powder. May be dissolved in DMSO (25 mg/ml).

Storage Conditions

Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month.

References

1. CJ Lai et al. Cancer Res. 2010, 70:3647
2. X Cai et al. J. Med. Chem. 2010, 53:2000

 
Chemical structure of CUDC-101.

Chemical structure of CUDC-101.